BBH — VanEck Biotech ETF
Data updated: 2026-05-28
BBH — VanEck Biotech ETF data: holdings, portfolio allocation, expenses, performance, cashflows, risk and SEC filings. United States Health Care Equity · $371.59M AUM · 0.35% expense ratio · 20.1% 1-yr return. From SEC regulatory filings.
BBH Fund Overview
BBH — VanEck Biotech ETF is a US ETF managed by VanEck ETF Trust, categorised as United States Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US ETF
- Manager: VanEck ETF Trust
- Category: United States Health Care Equity
- Assets under management: $371.59M
- 1-year return: 20.1%
- Ticker: BBH
- SEC CIK: 0001137360
- SEC series ID: S000034406
- Share class ID: C000105864
BBH Holdings
Top 10 holdings of VanEck Biotech ETF by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Gilead Sciences Inc | 14.63% |
| Amgen Inc | 14.54% |
| Vertex Pharmaceuticals Inc | 8.06% |
| Regeneron Pharmaceuticals Inc | 7.51% |
| Argenx SE | 5.28% |
| Insmed Inc | 4.59% |
| IQVIA Holdings Inc | 4.30% |
| Alnylam Pharmaceuticals Inc | 4.11% |
| Natera Inc | 3.98% |
| United Therapeutics Corp | 3.81% |
BBH Portfolio Allocation
Asset-class allocation of VanEck Biotech ETF by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 99.9% |
| Cash & Equivalents | 0.2% |
BBH Performance
Total returns for BBH (as of 2026-08-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | -0.6% |
| 1 year | 20.1% |
| 3 years (annualised) | 5.7% |
| 5 years (annualised) | 1.9% |
BBH Risk Information
Risk metrics for BBH, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 16.7%
BBH Costs and Fees
BBH costs about $35 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.35%
- Gross expense ratio: 0.35%
- Portfolio turnover: 19%
- Brokerage commissions: 1.30 bps of average net assets (SEC N-CEN)
BBH Cashflows
Over the 12 months to 2026-03, VanEck Biotech ETF had net outflows of $55.72M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-03 | $364.51K |
| 2026-02 | −$1.95M |
| 2026-01 | $69.04K |
| 2025-12 | −$191.34K |
| 2025-11 | $1.97M |
| 2025-10 | −$20.94M |
BBH Debt Constituents
No individual debt constituents are reported in VanEck Biotech ETF's latest SEC N-PORT filing.
BBH Prospectus and SEC Filings
Official VanEck Biotech ETF filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Other United States Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.